LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7% After Analyst Downgrade

by · The Cerbat Gem

LB Pharmaceuticals Inc (NASDAQ:LBRX – Get Free Report)’s stock price fell 7% during mid-day trading on Monday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The stock traded as low as $35.02 and last traded at $34.60. 76,497 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 281,304 shares. The stock had previously closed at $37.22.

LBRX has been the topic of several other reports. HC Wainwright restated a “buy” rating on shares of LB Pharmaceuticals in a research report on Monday. Raymond James Financial upgraded LB Pharmaceuticals to a “buy” rating in a report on Monday. Piper Sandler reissued an “overweight” rating and set a $78.00 price objective on shares of LB Pharmaceuticals in a research report on Monday, August 3rd. Canaccord Genuity Group initiated coverage on LB Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $65.00 price objective for the company. Finally, Wolfe Research started coverage on shares of LB Pharmaceuticals in a report on Tuesday, July 7th. They set an “outperform” rating and a $45.00 target price on the stock. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.40.

Check Out Our Latest Report on LBRX

Institutional Trading of LB Pharmaceuticals

A number of hedge funds have recently made changes to their positions in LBRX. Wellington Management Group LLP grew its stake in shares of LB Pharmaceuticals by 11.9% in the 2nd quarter. Wellington Management Group LLP now owns 58,891 shares of the company’s stock worth $1,911,000 after buying an additional 6,251 shares during the last quarter. Great Lakes Advisors LLC bought a new position in LB Pharmaceuticals during the 2nd quarter valued at approximately $987,000. Bank of New York Mellon Corp bought a new position in LB Pharmaceuticals during the 2nd quarter valued at approximately $1,784,000. Stempoint Capital LP purchased a new position in LB Pharmaceuticals during the first quarter valued at $1,233,000. Finally, Janus Henderson Group PLC purchased a new position in LB Pharmaceuticals during the first quarter valued at $1,613,000.

LB Pharmaceuticals Stock Down 3.2%

The company has a fifty day simple moving average of $43.52 and a 200 day simple moving average of $35.11. The firm has a market capitalization of $1.12 billion and a P/E ratio of -10.11.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.87). As a group, equities analysts expect that LB Pharmaceuticals Inc will post -5.70 earnings per share for the current fiscal year.

LB Pharmaceuticals Company Profile

(Get Free Report)

LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and neuropsychiatric disorders. The company’s lead product candidate is LB-102, an oral prodrug of amisulpride, an established antipsychotic medicine that is approved in certain countries outside the United States but is not currently approved in the U.S.

LB-102 is being developed for the treatment of schizophrenia, with the company seeking to evaluate its potential to address the needs of patients and healthcare providers in the U.S.

Further Reading